BIOKIN PHARMACEUTICAL(SH:688506) Shang Hai Zheng Quan Bao·2025-08-19 18:58Core Viewpoint - The company has conducted its semi-annual report for 2025, ensuring that all information disclosed is true, accurate, and complete, with no false records or misleading statements [1][4][10]. Group 1: Company Overview - The company is Sichuan Baili Tianheng Pharmaceutical Co., Ltd., with stock code 688506 and is listed on the Shanghai Stock Exchange [1][10]. - The company held its fourth Supervisory Board and Board meetings on August 19, 2025, to discuss and approve the semi-annual report and related matters [3][11]. Group 2: Financial Data - The company raised a total of RMB 990,470,000 from its initial public offering, with a net amount of RMB 884,397,430.28 after deducting issuance costs [29][30]. - As of June 30, 2025, the balance of the company's fundraising special account was RMB 13,164,522.54 [31]. Group 3: Fund Management - The company has established a fundraising management system to ensure the effective use of raised funds and protect investor interests [32]. - The company has implemented special account management for the raised funds, signing relevant agreements with underwriters and banks [33]. Group 4: Fund Usage - As of June 30, 2025, the company has not used any raised funds for pre-investment or replacement [36]. - The company has temporarily used RMB 60 million of idle raised funds to supplement working capital, with a commitment to return the funds to the special account within 12 months [38].